ClinicalTrials.gg
CompletedNCT03739203Updated Sep 21, 2022Results posted

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

A Phase 3 interventional study of Cariprazine and Placebo in Major Depressive Disorder, sponsored by AbbVie. Completed at 112 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
752
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Enrollment
9th of 53
752 · median 442
Started
2018
with 6 others
Phase 3
31 of 53
none open now
Registered
48th of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 9th largest by enrollment, is one of 7 that started in 2018, is one of 31 in phase 3, and was the 48th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • MDD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written has been obtained.
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]).
  • Participant must be an outpatient at the time of Visit 1 (Screening).
  • Participant meets the , Fifth Edition (DSM-5) criteria for MDD based on Structured Clinical Interview for DSM-5 (SCID-5), with a current major depressive episode of at least 8 weeks and not exceeding 24 months in duration at Visit 1/Screening. A diagnosis of MDD with psychotic features will be acceptable.
  • Diagnosis of MDD confirmed through a formal adjudication process.
  • Participant demonstrates ability to follow study instructions and likely to complete all required visits.
  • Participant must have an inadequate response, as measured by the modified antidepressant treatment response questionnaire (ATRQ), to 1 to 3 antidepressants administered during the current episode at an adequate dose (as per package insert) and for at least 6 weeks duration, with at least one dose escalation during the current depressive episode.
  • Only one antidepressant (of sufficient dose per package insert and taken for at least 6 weeks) will be allowed at randomization and Participants must agree to continue taking the same ADT dosing regimen through completion of Visit 6/early termination (ET). Participants who are taking more than one antidepressant at Screening, regardless of the indication, will need to discontinue all other antidepressants prior to Visit 2 (Baseline).
  • Male and female Participants must agree to use a medically acceptable and highly effective method of during the course of the entire study.
  • Women of (only) must have a negative serum β-human chorionic gonadotropin pregnancy test prior to Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any current psychiatric diagnosis other than MDD (including those with current intellectual development disability) with the exception of specific phobias.
  • Participant has a history of intolerance or to cariprazine or other drugs of the same class or to rescue medications.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
752 participants (actual)

Study arms

  • Placebo comparator
    Placebo + ADT

    Cariprazine matching placebo capsules, orally, once daily in addition to their ongoing antidepressant therapy (ADT) \[same antidepressant and dose of ADT they were on at the Baseline\] during the Double-blind Treatment Period, up to Week 6.

    Drug: Placebo · Drug: Antidepressant Therapy (ADT)

  • Experimental
    Cariprazine 1.5 mg/day + ADT

    Cariprazine 1.5 mg capsules, orally, once daily in addition to their ongoing ADT (same antidepressant and dose of ADT they were on at the Baseline) during the Double-blind Treatment Period, up to Week 6.

    Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)

  • Experimental
    Cariprazine 3 mg/day + ADT

    Cariprazine 1.5 mg capsules, orally, once daily for 2 weeks starting at the Baseline, titrated to 3.0 mg capsules, orally, once daily from Week 2 through Week 6 in addition to their ongoing ADT (same antidepressant and dose of ADT) during the Double-blind Treatment Period, up to Week 6.

    Drug: Cariprazine · Drug: Antidepressant Therapy (ADT)

Interventions

  • Cariprazine supplied in capsules

    Also known as: VRAYLAR®

  • DrugPlacebo

    Placebo supplied in capsules

  • DrugAntidepressant Therapy (ADT)

    ADT as prescribed by the physician per standard of care in clinical practice.

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score

    The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) was used for analyses.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score

    The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses.

    Time frame: Baseline and Week 6

07

Results

Posted Sep 21, 2022

Participant flow

Double-blind Treatment Period (6 Weeks)
Participant flow — Double-blind Treatment Period (6 Weeks)
MilestonePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Started250250251
Modified intent-to treat (mitt) population249250251
Completed235233226
Not completed151725
Withdrew: Adverse event6913
Withdrew: Lack of efficacy101
Withdrew: Lost to follow-up112
Withdrew: Withdrawal by subject446
Withdrew: Protocol deviation101
Withdrew: Non-compliance with study drug131
Withdrew: Reason not specified101
Safety Follow-Up Period (4 Weeks)
Participant flow — Safety Follow-Up Period (4 Weeks)
MilestonePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Started242242242
Completed240240238
Not completed224
Withdrew: Withdrawal by subject120
Withdrew: Lost to follow-up002
Withdrew: Death100
Withdrew: Reason not specified002

Outcome measures

PrimaryChange From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score

The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants were rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item was scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. The total score ranges from 0 to 60 with a higher score indicating more depression. A negative change from Baseline indicates improvement. Mixed-effects Model for Repeated Measures (MMRM) was used for analyses.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score
score on a scalePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) Total Score-13.4 ± 0.70-13.8 ± 0.69-14.8 ± 0.70
Statistical analysis
  • Placebo + ADT vs Cariprazine 1.5 mg/Day + ADT · MMRM · p = 0.6798 (p-value estimated by Mixed-effects Model for Repeated Measure from test of no difference between cariprazine dose group and placebo at Week 6.) · Least squares mean difference: -0.4 · 95% CI -2.10 to 1.37MMRM=Fixed effects:treatment group(TG),ADT failure category,visit,TG-by-visit;Covariates:Baseline(BL)value\& BL by-visit interaction.
  • Placebo + ADT vs Cariprazine 3 mg/Day + ADT · MMRM · p = 0.1245 (p-value estimated by Mixed-effects Model for Repeated Measure from test of no difference between cariprazine dose group and placebo at Week 6.) · Least squares mean difference: -1.4 · 95% CI -3.11 to 0.38MMRM=Fixed effects:treatment group(TG), ADT failure category,visit,TG-by-visit;Covariates:Baseline(BL)value\& BL by-visit interaction.
SecondaryChange From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score

The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score
score on a scalePlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) Score-1.4 ± 0.09-1.4 ± 0.09-1.6 ± 0.09
Statistical analysis
  • Placebo + ADT vs Cariprazine 1.5 mg/Day + ADT · MMRM · p = 0.5152 (p-value estimated by Mixed-effects Model for Repeated Measure from test of no difference between cariprazine dose group and placebo at Week 6.) · Least squares mean difference: -0.1 · 95% CI -0.29 to 0.15MMRM=Fixed effects:treatment group(TG),ADT failure category,visit,TG-by-visit;Covariates:Baseline(BL)value\& BL by-visit interaction.
  • Placebo + ADT vs Cariprazine 3 mg/Day + ADT · MMRM · p = 0.0573 (p-value estimated by Mixed-effects Model for Repeated Measure from test of no difference between cariprazine dose group and placebo at Week 6.) · Least squares mean difference: -0.2 · 95% CI -0.43 to 0.01MMRM=Fixed effects:treatment group(TG), ADT failure category,visit,TG-by-visit;Covariates:Baseline(BL)value\& BL by-visit interaction.

Adverse events

Collected over First dose of study drug until 30 days after the last dose of study drug (up to 12 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + ADT1/250 (0.4%)2/250 (0.8%)54/250 (21.6%)
Cariprazine 1.5 mg/Day + ADT0/250 (0%)3/250 (1.2%)70/250 (28%)
Cariprazine 3 mg/Day + ADT0/251 (0%)1/251 (0.4%)85/251 (33.9%)
Most frequent serious events
Most frequent serious events
EventPlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/2500/2500/251
DEATHGeneral disorders1/2500/2500/251
ANIMAL BITEInjury, poisoning and procedural complications0/2501/2500/251
FALLInjury, poisoning and procedural complications0/2501/2500/251
FIBULA FRACTUREInjury, poisoning and procedural complications0/2501/2500/251
LIGAMENT SPRAINInjury, poisoning and procedural complications0/2501/2500/251
SUICIDE ATTEMPTPsychiatric disorders0/2501/2500/251
ATRIAL FIBRILLATIONCardiac disorders0/2500/2501/251
Most frequent other events
Most frequent other events
EventPlacebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADT
AKATHISIANervous system disorders9/25019/25029/251
HEADACHENervous system disorders27/25024/25027/251
INSOMNIAPsychiatric disorders9/25016/25025/251
SOMNOLENCENervous system disorders11/25012/25017/251
NAUSEAGastrointestinal disorders10/25014/25016/251

Baseline characteristics

Safety Population included all participants in the randomized population who took ≥1 dose of double-blind investigational product.

Age, Continuous
Age, Continuous(years)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Mean46.2 ± 12.1245.0 ± 12.9545.8 ± 12.4545.7 ± 12.51
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Female191185197573
Male596554178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Hispanic or Latino303834102
Not Hispanic or Latino220212217649
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
American Indian or Alaska Native0022
Asian4059
Native Hawaiian or Other Pacific Islander0101
Black or African American29322283
White217216221654
More than one race0112
Unknown or Not Reported0000
Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Montgomery-Asberg Depression Rating Scale (MADRS) Total Score(score on a scale)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Mean32.99 ± 4.78932.00 ± 4.24632.25 ± 4.68832.41 ± 4.593
Clinical Global Impression-Severity (CGI-S) Scale Score
Clinical Global Impression-Severity (CGI-S) Scale Score(score on a scale)Placebo + ADTCariprazine 1.5 mg/Day + ADTCariprazine 3 mg/Day + ADTTotal
Mean4.67 ± 0.5994.61 ± 0.5864.65 ± 0.6544.64 ± 0.614
08

Study locations

112 sites
  • Harmonex /ID# 236936
    Dothan, Alabama 36303, United States
  • Woodland International Research Group /ID# 236349
    Little Rock, Arkansas 72211, United States
  • California Pharmaceutical Research Institute /ID# 236731
    Anaheim, California 92804-3738, United States
  • Axiom Research /ID# 236267
    Colton, California 92324, United States
  • Global Clinical Trials /ID# 235059
    Costa Mesa, California 92627, United States
  • Collaborative Neuroscience Research - Orange County /ID# 237637
    Garden Grove, California 92845, United States
  • Behavioral Research Specialists, LLC /ID# 236622
    Glendale, California 91206-4261, United States
  • Sun Valley Research Center /ID# 236560
    Imperial, California 92251-9401, United States
  • North County Clinical Research /ID# 235014
    Oceanside, California 92054, United States
  • Excell Research, Inc /ID# 237717
    Oceanside, California 92056, United States
  • NRC Research Institute /ID# 234632
    Orange, California 92868, United States
  • Anderson Clinical Research /ID# 236624
    Redlands, California 92374-4555, United States
  • Syrentis Clinical Research /ID# 237408
    Santa Ana, California 92705, United States
  • California Neuroscience Research Medical Group, Inc. /ID# 236636
    Sherman Oaks, California 91403-2109, United States
  • Schuster Medical Research Institute /ID# 236445
    Sherman Oaks, California 91403, United States
  • Pacific Clinical Research Management Group /ID# 234378
    Upland, California 91786-3676, United States
  • MCB Clinical Research Centers /ID# 236927
    Colorado Springs, Colorado 80910, United States
  • CT Clinical Research /ID# 234638
    Cromwell, Connecticut 06416, United States
  • Innovative Clinical Research /ID# 235186
    Fort Lauderdale, Florida 33319, United States
  • Gulfcoast Clinical Research Center /ID# 236280
    Fort Myers, Florida 33912, United States
  • Innova Clinical Trials /ID# 237376
    Miami, Florida 33133, United States
  • International Research Associates, LLC /ID# 237410
    Miami, Florida 33183, United States
  • Medical Research Group of Central Florida /ID# 237326
    Orange City, Florida 32763, United States
  • Clinical Neuroscience Solutions, Inc /ID# 236604
    Orlando, Florida 32801-2986, United States
  • Space Coast Neuropsychiatric Research Institute /ID# 235766
    Palm Bay, Florida 32905, United States
  • Atlanta Center for Medical Research /ID# 234696
    Atlanta, Georgia 30331, United States
  • Institute for Advanced Medical Research /ID# 234992
    Atlanta, Georgia 30341, United States
  • iResearch Savannah /ID# 236082
    Savannah, Georgia 31405, United States
  • Iris Research Inc. /ID# 234995
    Smyrna, Georgia 30082-2629, United States
  • AMR Conventions Research /ID# 236262
    Naperville, Illinois 60563, United States
  • Collective Medical Research /ID# 236397
    Prairie Village, Kansas 66208, United States
  • Boston Clinical Trials /ID# 236558
    Boston, Massachusetts 02131-2515, United States
  • BTC of New Bedford /ID# 236381
    New Bedford, Massachusetts 02740, United States
  • The Coastal Research Associates Inc /ID# 235056
    South Weymouth, Massachusetts 02190, United States
  • Sisu at Renaissance Medical Group /ID# 236198
    Springfield, Massachusetts 01103, United States
  • Center for Emotional Fitness /ID# 236630
    Cherry Hill, New Jersey 08002-3008, United States
  • Bio Behavioral Health, Inc /ID# 238209
    Toms River, New Jersey 08755-6434, United States
  • SPRI Clinical Trails /ID# 236657
    Brooklyn, New York 11235-5660, United States
  • Bioscience Research /ID# 234961
    Mount Kisco, New York 10549-3028, United States
  • Fieve Clinical Research, Inc. /ID# 236632
    New York, New York 10017-1921, United States
  • Eastside Comprehensive Medical Center LLC /ID# 236094
    New York, New York 10128, United States
  • Clinical Trials America /ID# 237636
    Hickory, North Carolina 28601, United States
  • Quest Therapeutics of Avon Lake /ID# 236281
    Avon Lake, Ohio 44012, United States
  • Patient Priority Clinical Sites, LLC /ID# 236743
    Cincinnati, Ohio 45215-2123, United States
  • North Star Medical Research LL /ID# 235076
    Middleburg Heights, Ohio 44130, United States
  • CincyScience /ID# 236387
    West Chester, Ohio 45069, United States
  • Lynn Health Science Institute (LHSI) /ID# 237612
    Oklahoma City, Oklahoma 73112, United States
  • Central States Research /ID# 238295
    Tulsa, Oklahoma 74136, United States
  • Oregon Ctr for Clin Inv /ID# 237463
    Salem, Oregon 97301, United States
  • Keystone Clinical Studies LLC /ID# 238153
    Plymouth Meeting, Pennsylvania 19462, United States
  • Psychiatric Consultants PC /ID# 235838
    Franklin, Tennessee 37067, United States
  • Research Strategies of Memphis /ID# 236629
    Memphis, Tennessee 38119-5202, United States
  • Earle Research /ID# 236660
    Friendswood, Texas 77546, United States
  • AIM Trials /ID# 236366
    Plano, Texas 75093, United States
  • Clinical Trials of Texas, Inc /ID# 237864
    San Antonio, Texas 78229, United States
  • Family Psychiatry of The Woodlands /ID# 236423
    The Woodlands, Texas 77381, United States
  • Woodstock Research Center /ID# 236653
    Woodstock, Vermont 05091-9795, United States
  • SSM Health Dean Medical Group /ID# 238103
    Madison, Wisconsin 53715, United States
  • Chatham-Kent Clinical Trials /ID# 235707
    Chatham, Ontario N7L 1C1, Canada
  • Introspect Clinical Research Centre /ID# 235987
    Ottawa, Ontario K1C 1T1, Canada
  • Recherches Neuro-Hippocampe Inc. d/b/a Ottawa Memory Clinic /ID# 235890
    Ottawa, Ontario K1Z 1G3, Canada
  • Diex Recherche Sherbrooke Inc. /ID# 234385
    Sherbrooke, Quebec J1L 0H8, Canada
  • Medical Services Prague /ID# 235109
    Prague, Praha, Hlavni Mesto 160 00, Czechia
  • Saint Anne s.r.o. /ID# 235060
    Brno, 602 00, Czechia
  • MUDr. Marta Holanova /ID# 235126
    Brno, 615 00, Czechia
  • Neuropsychiatriehk s.r.o. /ID# 236195
    Hradec Králové, 503 41, Czechia
  • A-SHINE s.r.o. /ID# 236370
    Pilsen, 301 00, Czechia
  • CLINTRIAL s.r.o. /ID# 237794
    Prague, 100 00, Czechia
  • INEP medical s.r.o. /ID# 236291
    Prague, 186 00, Czechia
  • Helsingin psykiatripalvelu /ID# 235090
    Helsinki, 00260, Finland
  • Mederon Oy /ID# 235057
    Helsinki, 00270, Finland
  • Savon Psykiatripalvelu Oy /ID# 235028
    Kuopio, 70100, Finland
  • Oulu Mentalcare Oy /ID# 235089
    Oulu, 90100, Finland
  • Satakunnan Psykiatripalvelu Oy /ID# 234936
    Rauma, 26100, Finland
  • Psykiatri- ja psykologikeskus Mentoria /ID# 235091
    Tampere, 33200, Finland
  • Centrum Medyczne Luxmed /ID# 235110
    Lublin, Lublin Voivodeship 20-109, Poland
  • Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 237466
    Gdansk, Pomeranian Voivodeship 80-546, Poland
  • Zachodniopomorski Instytut Psychoterapii /ID# 236549
    Szczecin, West Pomeranian Voivodeship 70-486, Poland
  • Wlokiennicza Med /ID# 235105
    Bia?ystok, 15-464, Poland
  • MlynowaMed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk /ID# 235065
    Bialystok, 15-404, Poland
  • Przychodnia Srodmiescie Sp. Z o.o. /ID# 236197
    Bydgoszcz, 85-080, Poland
  • Med-Art /Id# 234986
    Bydgoszcz, 85-156, Poland
  • Poradnia Zdrowia Psychicznego /ID# 234750
    Chełmno, 86-200, Poland
  • Centrum Zdrowia Psychicznego BioMed - Jan Latala /ID# 235064
    Kielce, 25-411, Poland
  • Nzop Mentis /Id# 235062
    Leszno, 64-100, Poland
  • Centrum Medyczne Neuromedica /ID# 235615
    Lublin, 20-831, Poland
  • Krzysztof Klinke Prywatny Gabinet Psychiatryczny /ID# 235061
    Sosnowiec, 41-200, Poland
  • Gabinet Lekarski Torunskie Centrum Psychiatrii Neuromed /ID# 235001
    Torun, 87-100, Poland
  • Osrodek Badan Klinicznych Clinsante /ID# 234990
    Torun, 87-100, Poland
  • Przychodnia Lekarsko-Psychologiczna PERSONA /ID# 235007
    Wroclaw, 50-227, Poland
  • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski /ID# 234851
    Bełchatów, Łódź Voivodeship 97-400, Poland
  • INSPIRA Clinical Research /ID# 234542
    San Juan, 00918, Puerto Rico
  • Military Medical Academy /ID# 237062
    Belgrade, Beograd 11000, Serbia
  • University Clinical Center Serbia /ID# 237747
    Belgrade, Beograd 11000, Serbia
  • University Clinical Center of Nis /ID# 236973
    Niš, Nisavski Okrug 18000, Serbia
  • University Clinical Center Kragujevac /ID# 237750
    Kragujevac, Sumadijski Okrug 34000, Serbia
  • University Clinical Center Kragujevac /ID# 237752
    Kragujevac, Sumadijski Okrug 34000, Serbia
  • University Clinical Center Kragujevac /ID# 237753
    Kragujevac, Sumadijski Okrug 34000, Serbia
  • Bel Medic - General Hospital /ID# 236171
    Belgrade, 11000, Serbia
  • Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 234299
    Belgrade, 11040, Serbia

Showing the first 100 of 112 sites across 8 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Riesenberg R, Yeung PP, Rekeda L, Sachs GS, Kerolous M, Fava M. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study. J Clin Psychiatry. 2023 Aug 16;84(5):22m14643. doi: 10.4088/JCP.22m14643. PubMed 37585254 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2021, 33 months.

Results were first posted in Sep 2022, 1 year after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 33 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 13, 2018
StartActual
Nov 10, 2018
Primary completionActual
Sep 6, 2021
CompletionActual
Sep 6, 2021
Results first posted
Sep 21, 2022
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03739203
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Nov 10, 2018
Primary completion
Sep 6, 2021
Completion
Sep 6, 2021
Results posted
Sep 21, 2022
Last update
Sep 21, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cariprazine

Start the discussion